Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Anand Devaraj et al.|The Lancet Respiratory Medicine|2020Cited by 558
Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosisPaul Beirne, Peter Kelleher, P. Pantelidis et al.|European Respiratory Journal|2009Cited by 65